이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

국소 근육 침윤성 방광암 환자 치료에서 아테졸리주맙을 포함하거나 포함하지 않는 화학방사선 요법

2026년 11월 10일 업데이트: National Cancer Institute (NCI)

국소 근육 침윤성 방광암에서 아테졸리주맙을 병용하거나 병용하지 않는 병행 화학방사선 요법의 3상 무작위 시험

This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in treating patients with localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy without atezolizumab.

연구 개요

상태

상태

현재 모집 상태 또는 확장 액세스 상태를 나타냅니다.
모집하지 않고 적극적으로

정황

정황

연구 중인 질병, 장애, 증후군, 질환 또는 부상입니다. ClinicalTrials.gov에서 조건에는 수명, 삶의 질 및 건강 위험과 같은 기타 건강 관련 문제도 포함될 수 있습니다.

개입 / 치료

개입 / 치료

임상 연구의 초점이 되는 프로세스 또는 작업입니다. 개입에는 약물, 의료 기기, 절차, 백신 및 조사 중이거나 이미 사용 가능한 기타 제품이 포함됩니다. 개입에는 교육이나 식이요법 및 운동 수정과 같은 비침습적 접근법도 포함될 수 있습니다.

상세 설명

PRIMARY OBJECTIVE:

I. To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).

SECONDARY OBJECTIVES:

I. To compare overall survival between the two arms. II. To compare modified bladder intact event-free survival including cancer related death between arms.

III. To compare complete and partial pathologic response between arms at 3 months after completing chemoradiation therapy.

IV. To estimate metastases-free survival by arm. V. To compare the qualitative and quantitative adverse events from each arm. VI. To estimate the rate of non-muscle invasive bladder cancer recurrence by arm.

VII. To estimate the rate of salvage cystectomy and reasons for cystectomy by arm.

VIII. To compare mean patient-reported global quality of life (QOL) at week 54 using the European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ)-Core (C)30 Global Health Status (GHS) subscale score between patients with localized muscle-invasive bladder cancer randomized to chemoradiation with versus (vs.) without atezolizumab.

TRANSLATIONAL MEDICINE OBJECTIVES:

I. To test the hypothesis that a panel of validated biomarkers of concurrent CRT involving nuclear MRE11, impaired deoxyribonucleic acid damage response (DDR) function and tumor subtyping will be prognostic for BI-EFS among patients receiving either concurrent CRT or chemoimmuno-radiotherapy (CIRT) of the primary tumor.

II. To test the hypothesis that tumor total mutation burden, neoantigen burden, infiltrating immune response, PD-L1 expression and T cell response are associated with augmented response after concurrent CIRT.

III. To bank urine specimens for future use.

PATIENT-REPORTED OUTCOMES (PROs) OBJECTIVES:

I. To compare mean patient-reported global QOL as measured by the EORTC QLQ-C30 Global Health Status subscale scores at week 54 between patients with localized muscle-invasive bladder cancer randomized to chemoradiation with vs. without atezolizumab. (Primary) II. To compare mean patient-reported bowel symptoms at each assessment time by arm using the Expanded Prostate Cancer Index Composite (EPIC) Bowel Assessment from the Expanded Prostate Index, the bladder-specific supplement to the QLQ-C30, the EORTC QLQ-Muscle Invasive Bladder Cancer (BLM30), the Physical Functioning subscale of the EORTC QLQ-C30, and overall health status using the EuroQol Five Dimension Five Level Scale (EQ-5D-5L). (Exploratory) III. To compare longitudinal change over time by arm in patient-reported global QOL using the EORTC QLQ-C30, the Bowel Domain of the Expanded Prostate Index (EPIC Bowel Assessment), the bladder-specific supplement to the QLQ-C30, the EORTC QLQ-BLM30, the Physical Functioning subscale of the EORTC QLQ-C30, and overall health status using the EQ-5D-5L. (Exploratory)

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo radiation therapy (RT) (3 dimensional [D] CRT or intensity-modulated radiation therapy [IMRT]) daily Monday-Friday for up to 7-8 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine intravenously (IV) twice weekly for 6 weeks concurrent with RT, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity. Patients also undergo a transurethral resection of bladder tumor (TURBT) at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6 months through year 5 and computed tomography (CT) or magnetic resonance imaging (MRI) at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.

ARM II: Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6 months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.

After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 3 years.

연구 유형

연구 유형

임상 연구의 특성을 설명합니다. 연구 유형에는 중재 연구(임상 시험이라고도 함), 관찰 연구(환자 등록 포함) 및 확장된 액세스가 포함됩니다.
중재적

등록 (추정된)

등록

임상 연구의 참가자 수. "예상" 등록은 연구원이 연구에 필요한 참가자의 목표 수입니다.
475

단계

단계

미국 식품의약국(FDA)에서 개발한 정의에 따라 약물 또는 생물학적 제품을 연구하는 임상 시험 단계입니다. 이 단계는 연구의 목적, 참가자 수 및 기타 특성을 기반으로 합니다. 초기 1단계(이전에는 0단계로 나열됨), 1단계, 2단계, 3단계 및 4단계의 5단계가 있습니다. 해당 없음은 장치 또는 행동 개입의 시험을 포함하여 FDA에서 정의한 단계가 없는 시험을 설명하는 데 사용됩니다.
  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 미국
    • Arizona
      • Phoenix, Arizona, 미국, 85054
        • Mayo Clinic Hospital in Arizona
      • Scottsdale, Arizona, 미국, 85259
        • Mayo Clinic in Arizona
      • Tucson, Arizona, 미국, 85719
        • Banner University Medical Center - Tucson
      • Tucson, Arizona, 미국, 85719
        • University of Arizona Cancer Center-North Campus
    • California
      • Auburn, California, 미국, 95602
        • Sutter Auburn Faith Hospital
      • Auburn, California, 미국, 95603
        • Sutter Cancer Centers Radiation Oncology Services-Auburn
      • Berkeley, California, 미국, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Carmichael, California, 미국, 95608
        • Mercy San Juan Medical Center
      • Carmichael, California, 미국, 95608
        • Mercy Cancer Center - Carmichael
      • Elk Grove, California, 미국, 95758
        • Mercy Cancer Center - Elk Grove
      • La Jolla, California, 미국, 92093
        • UC San Diego Moores Cancer Center
      • Los Angeles, California, 미국, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, 미국, 90048
        • Cedars-Sinai Medical Center
      • Los Angeles, California, 미국, 90033
        • Los Angeles General Medical Center
      • Marysville, California, 미국, 95901
        • Fremont - Rideout Cancer Center
      • Modesto, California, 미국, 95355
        • Memorial Medical Center
      • Orange, California, 미국, 92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • Palo Alto, California, 미국, 94301
        • Palo Alto Medical Foundation Health Care
      • Rocklin, California, 미국, 95765
        • Mercy Cancer Center - Rocklin
      • Roseville, California, 미국, 95661
        • Sutter Cancer Centers Radiation Oncology Services-Roseville
      • Roseville, California, 미국, 95661
        • Sutter Roseville Medical Center
      • Sacramento, California, 미국, 95816
        • Sutter Medical Center Sacramento
      • Sacramento, California, 미국, 95817
        • University of California Davis Comprehensive Cancer Center
      • Sacramento, California, 미국, 95816
        • Mercy Cancer Center - Sacramento
      • San Luis Obispo, California, 미국, 93401
        • Pacific Central Coast Health Center-San Luis Obispo
      • Sunnyvale, California, 미국, 94086
        • Palo Alto Medical Foundation-Sunnyvale
      • Woodland, California, 미국, 95695
        • Woodland Memorial Hospital
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • UCHealth University of Colorado Hospital
      • Boulder, Colorado, 미국, 80304
        • Rocky Mountain Cancer Centers-Boulder
      • Colorado Springs, Colorado, 미국, 80909
        • UCHealth Memorial Hospital Central
      • Colorado Springs, Colorado, 미국, 80920
        • Memorial Hospital North
      • Edwards, Colorado, 미국, 81632
        • Shaw Cancer Center
      • Fort Collins, Colorado, 미국, 80524
        • Poudre Valley Hospital
      • Fort Collins, Colorado, 미국, 80528
        • Cancer Care and Hematology-Fort Collins
      • Greeley, Colorado, 미국, 80631
        • UCHealth Greeley Hospital
      • Greeley, Colorado, 미국, 80631
        • Banner North Colorado Medical Center
      • Loveland, Colorado, 미국, 80538
        • Medical Center of the Rockies
      • Loveland, Colorado, 미국, 80539
        • Banner North Colorado Medical Center - Loveland Campus
    • Connecticut
      • Greenwich, Connecticut, 미국, 06830
        • Smilow Cancer Hospital Care Center at Greenwich
      • Guilford, Connecticut, 미국, 06437
        • Smilow Cancer Hospital Care Center - Guilford
      • Hartford, Connecticut, 미국, 06102
        • Hartford Hospital
      • Meriden, Connecticut, 미국, 06451
        • Midstate Medical Center
      • New Britain, Connecticut, 미국, 06050
        • The Hospital of Central Connecticut
      • New Haven, Connecticut, 미국, 06520
        • Yale University
      • North Haven, Connecticut, 미국, 06473
        • Yale-New Haven Hospital North Haven Medical Center
      • Trumbull, Connecticut, 미국, 06611
        • Smilow Cancer Hospital Care Center-Trumbull
      • Waterford, Connecticut, 미국, 06385
        • Smilow Cancer Hospital Care Center - Waterford
    • Delaware
      • Millville, Delaware, 미국, 19967
        • Beebe South Coastal Health Campus
      • Newark, Delaware, 미국, 19713
        • Helen F Graham Cancer Center
      • Newark, Delaware, 미국, 19713
        • Medical Oncology Hematology Consultants PA
      • Rehoboth Beach, Delaware, 미국, 19971
        • Beebe Health Campus
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20016
        • Sibley Memorial Hospital
    • Florida
      • Aventura, Florida, 미국, 33180
        • Mount Sinai Comprehensive Cancer Center at Aventura
      • Coral Gables, Florida, 미국, 33146
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
      • Deerfield Beach, Florida, 미국, 33442
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
      • Gainesville, Florida, 미국, 32610
        • UF Health Cancer Institute - Gainesville
      • Miami, Florida, 미국, 33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Miami Beach, Florida, 미국, 33140
        • Mount Sinai Medical Center
      • N. Venice, Florida, 미국, 34275
        • Sarasota Memorial Hospital-Venice
      • Sarasota, Florida, 미국, 34239
        • Sarasota Memorial Hospital
      • Sarasota, Florida, 미국, 34232
        • Florida Cancer Specialists - Sarasota
      • Sarasota, Florida, 미국, 34239
        • First Physicians Group - Urology Robotic and Minimally Invasive Surgery
      • Sarasota, Florida, 미국, 34243
        • Sarasota Memorial Health Care Center at University Parkway
      • Sarasota, Florida, 미국, 34239
        • Florida Cancer Specialists - Sarasota Downtown
      • Tampa, Florida, 미국, 33612
        • Moffitt Cancer Center
    • Georgia
      • Atlanta, Georgia, 미국, 30308
        • Emory University Hospital Midtown
      • Atlanta, Georgia, 미국, 30322
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, 미국, 30342
        • Emory Saint Joseph's Hospital
      • Newnan, Georgia, 미국, 30265
        • CTCA at Southeastern Regional Medical Center
    • Hawaii
      • Honolulu, Hawaii, 미국, 96813
        • Queen's Medical Center
      • Honolulu, Hawaii, 미국, 96817
        • The Cancer Center of Hawaii-Liliha
      • Honolulu, Hawaii, 미국, 96813
        • Hawaii Cancer Care Inc - Waterfront Plaza
      • Honolulu, Hawaii, 미국, 96813
        • Queen's Cancer Cenrer - POB I
      • Honolulu, Hawaii, 미국, 96813
        • Straub Clinic and Hospital
      • Honolulu, Hawaii, 미국, 96817
        • Queen's Cancer Center - Kuakini
      • ‘Aiea, Hawaii, 미국, 96701
        • Hawaii Cancer Care - Westridge
      • ‘Aiea, Hawaii, 미국, 96701
        • Pali Momi Medical Center
      • ‘Aiea, Hawaii, 미국, 96701
        • The Cancer Center of Hawaii-Pali Momi
    • Illinois
      • Barrington, Illinois, 미국, 60010
        • Advocate Good Shepherd Hospital
      • Bloomington, Illinois, 미국, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, 미국, 61520
        • Illinois CancerCare-Canton
      • Carthage, Illinois, 미국, 62321
        • Illinois CancerCare-Carthage
      • Chicago, Illinois, 미국, 60611
        • Northwestern University
      • Chicago, Illinois, 미국, 60657
        • Advocate Illinois Masonic Medical Center
      • Chicago, Illinois, 미국, 60612
        • Rush MD Anderson Cancer Center
      • Crystal Lake, Illinois, 미국, 60014
        • AMG Crystal Lake - Oncology
      • DeKalb, Illinois, 미국, 60115
        • Northwestern Medicine Cancer Center Kishwaukee
      • Decatur, Illinois, 미국, 62526
        • Decatur Memorial Hospital
      • Downers Grove, Illinois, 미국, 60515
        • Advocate Good Samaritan Hospital
      • Effingham, Illinois, 미국, 62401
        • Crossroads Cancer Center
      • Elgin, Illinois, 미국, 60123
        • Advocate Sherman Hospital
      • Elmhurst, Illinois, 미국, 60126
        • Elmhurst Memorial Hospital
      • Eureka, Illinois, 미국, 61530
        • Illinois CancerCare-Eureka
      • Evanston, Illinois, 미국, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Galesburg, Illinois, 미국, 61401
        • Western Illinois Cancer Treatment Center
      • Galesburg, Illinois, 미국, 61401
        • Illinois CancerCare-Galesburg
      • Geneva, Illinois, 미국, 60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview, Illinois, 미국, 60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Hazel Crest, Illinois, 미국, 60429
        • Advocate South Suburban Hospital
      • Highland Park, Illinois, 미국, 60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Hines, Illinois, 미국, 60141
        • Edward Hines Jr VA Hospital
      • Kewanee, Illinois, 미국, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Libertyville, Illinois, 미국, 60048
        • Condell Memorial Hospital
      • Libertyville, Illinois, 미국, 60048
        • AMG Libertyville - Oncology
      • Macomb, Illinois, 미국, 61455
        • Illinois CancerCare-Macomb
      • Maywood, Illinois, 미국, 60153
        • Loyola University Medical Center
      • Naperville, Illinois, 미국, 60540
        • Edward Hospital/Cancer Center
      • Oak Lawn, Illinois, 미국, 60453-2699
        • Advocate Christ Medical Center
      • Ottawa, Illinois, 미국, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Park Ridge, Illinois, 미국, 60068
        • Advocate Lutheran General Hospital
      • Pekin, Illinois, 미국, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, 미국, 61636
        • Methodist Medical Center of Illinois
      • Peoria, Illinois, 미국, 61637
        • OSF Saint Francis Medical Center
      • Peoria, Illinois, 미국, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, 미국, 61354
        • Illinois CancerCare-Peru
      • Princeton, Illinois, 미국, 61356
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, 미국, 62702
        • Springfield Clinic
      • Springfield, Illinois, 미국, 62781
        • Springfield Memorial Hospital
      • Urbana, Illinois, 미국, 61801
        • Carle Cancer Center
      • Warrenville, Illinois, 미국, 60555
        • Northwestern Medicine Cancer Center Warrenville
      • Washington, Illinois, 미국, 61571
        • Illinois CancerCare - Washington
    • Indiana
      • Indianapolis, Indiana, 미국, 46219
        • Community Cancer Center East
      • Indianapolis, Indiana, 미국, 46227
        • Community Cancer Center South
      • Indianapolis, Indiana, 미국, 46256
        • Community Cancer Center North
      • Richmond, Indiana, 미국, 47374
        • Reid Health
    • Iowa
      • Ames, Iowa, 미국, 50010
        • Mary Greeley Medical Center
      • Ames, Iowa, 미국, 50010
        • McFarland Clinic - Ames
      • Clive, Iowa, 미국, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, 미국, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Creston, Iowa, 미국, 50801
        • Greater Regional Medical Center
      • Des Moines, Iowa, 미국, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, 미국, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, 미국, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • West Des Moines, Iowa, 미국, 50266
        • Mercy Medical Center-West Lakes
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • University of Kansas Cancer Center
      • Overland Park, Kansas, 미국, 66210
        • University of Kansas Cancer Center-Overland Park
      • Westwood, Kansas, 미국, 66205
        • University of Kansas Hospital-Westwood Cancer Center
      • Wichita, Kansas, 미국, 67214
        • Ascension Via Christi Hospitals Wichita
    • Kentucky
      • Lexington, Kentucky, 미국, 40536
        • University of Kentucky/Markey Cancer Center
      • Lexington, Kentucky, 미국, 40503
        • Baptist Health Lexington
      • Louisville, Kentucky, 미국, 40202
        • The James Graham Brown Cancer Center at University of Louisville
      • Louisville, Kentucky, 미국, 40207
        • Baptist Health Louisville
    • Louisiana
      • Baton Rouge, Louisiana, 미국, 70809
        • Louisiana Hematology Oncology Associates LLC
      • Baton Rouge, Louisiana, 미국, 70809
        • Mary Bird Perkins Cancer Center
      • Metairie, Louisiana, 미국, 70006
        • East Jefferson General Hospital
      • Metairie, Louisiana, 미국, 70006
        • LSU Healthcare Network / Metairie Multi-Specialty Clinic
      • New Orleans, Louisiana, 미국, 70112
        • University Medical Center New Orleans
    • Maine
      • Bath, Maine, 미국, 04530
        • MaineHealth Coastal Cancer Treatment Center
      • Belfast, Maine, 미국, 04915
        • MaineHealth Waldo Hospital
      • Biddeford, Maine, 미국, 04005
        • MaineHealth Maine Medical Center - Biddeford
      • Norway, Maine, 미국, 04268
        • MaineHealth Stephens Hospital
      • Portland, Maine, 미국, 04102
        • MaineHealth Maine Medical Center - Portland
      • Rockport, Maine, 미국, 04856
        • Penobscot Bay Medical Center
      • Sanford, Maine, 미국, 04073
        • MaineHealth Cancer Care Center of York County
      • Sanford, Maine, 미국, 04073
        • MaineHealth Cancer Care and IV Therapy - Sanford
      • Scarborough, Maine, 미국, 04074
        • MaineHealth Maine Medical Center- Scarborough
      • South Portland, Maine, 미국, 04106
        • MaineHealth Cancer Care and IV Therapy - South Portland
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, 미국, 02114
        • Massachusetts General Hospital Cancer Center
      • Lowell, Massachusetts, 미국, 01854
        • Lowell General Hospital
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • University of Michigan Rogel Cancer Center
      • Ann Arbor, Michigan, 미국, 48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Battle Creek, Michigan, 미국, 49017
        • Bronson Battle Creek
      • Brighton, Michigan, 미국, 48116
        • University of Michigan - Brighton Center for Specialty Care
      • Brighton, Michigan, 미국, 48114
        • Trinity Health Medical Center - Brighton
      • Canton, Michigan, 미국, 48188
        • Trinity Health Medical Center - Canton
      • Chelsea, Michigan, 미국, 48118
        • Chelsea Hospital
      • Clarkston, Michigan, 미국, 48346
        • Michigan Healthcare Professionals Clarkston
      • Dearborn, Michigan, 미국, 48124
        • Corewell Health Dearborn Hospital
      • Detroit, Michigan, 미국, 48202
        • Henry Ford Hospital
      • Detroit, Michigan, 미국, 48201
        • Wayne State University/Karmanos Cancer Institute
      • Detroit, Michigan, 미국, 48236
        • Henry Ford Health Saint John Hospital
      • Farmington Hills, Michigan, 미국, 48334
        • Weisberg Cancer Treatment Center
      • Farmington Hills, Michigan, 미국, 48334
        • Michigan Healthcare Professionals Farmington
      • Farmington Hills, Michigan, 미국, 48336
        • Corewell Health Farmington Hills Hospital
      • Kalamazoo, Michigan, 미국, 49007
        • West Michigan Cancer Center
      • Lansing, Michigan, 미국, 48912
        • University of Michigan Health - Sparrow Lansing
      • Livonia, Michigan, 미국, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Macomb, Michigan, 미국, 48044
        • Henry Ford Saint John Hospital - Macomb Medical
      • Madison Heights, Michigan, 미국, 48071
        • Michigan Healthcare Professionals Madison Heights
      • Pontiac, Michigan, 미국, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Pontiac, Michigan, 미국, 48341
        • Michigan Healthcare Professionals Pontiac
      • Royal Oak, Michigan, 미국, 48073
        • Corewell Health William Beaumont University Hospital
      • Saginaw, Michigan, 미국, 48601
        • MyMichigan Medical Center Saginaw
      • Traverse City, Michigan, 미국, 49684
        • Munson Medical Center
      • Troy, Michigan, 미국, 48098
        • Michigan Healthcare Professionals Troy
      • Troy, Michigan, 미국, 48085
        • Corewell Health Beaumont Troy Hospital
      • Warren, Michigan, 미국, 48093
        • Henry Ford Health Warren Hospital
      • West Bloomfield, Michigan, 미국, 48322
        • Henry Ford West Bloomfield Hospital
      • Wyoming, Michigan, 미국, 49519
        • University of Michigan Health - West
    • Minnesota
      • Bemidji, Minnesota, 미국, 56601
        • Sanford Joe Lueken Cancer Center
      • Coon Rapids, Minnesota, 미국, 55433
        • Mercy Hospital
      • Duluth, Minnesota, 미국, 55805
        • Miller-Dwan Hospital
      • Edina, Minnesota, 미국, 55435
        • Fairview Southdale Hospital
      • Fridley, Minnesota, 미국, 55432
        • Unity Hospital
      • Monticello, Minnesota, 미국, 55362
        • Monticello Cancer Center
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic in Rochester
      • Saint Cloud, Minnesota, 미국, 56303
        • Coborn Cancer Center at Saint Cloud Hospital
      • Saint Louis Park, Minnesota, 미국, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul, Minnesota, 미국, 55101
        • Regions Hospital
    • Missouri
      • Bonne Terre, Missouri, 미국, 63628
        • Parkland Health Center-Bonne Terre
      • Cape Girardeau, Missouri, 미국, 63703
        • Saint Francis Medical Center
      • City of Saint Peters, Missouri, 미국, 63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, 미국, 63141
        • Siteman Cancer Center at West County Hospital
      • Kansas City, Missouri, 미국, 64154
        • University of Kansas Cancer Center - North
      • Lee's Summit, Missouri, 미국, 64064
        • University of Kansas Cancer Center - Lee's Summit
      • Saint Joseph, Missouri, 미국, 64506
        • Heartland Regional Medical Center
      • Sainte Genevieve, Missouri, 미국, 63670
        • Sainte Genevieve County Memorial Hospital
      • Springfield, Missouri, 미국, 65807
        • CoxHealth South Hospital
      • St Louis, Missouri, 미국, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, 미국, 63129
        • Siteman Cancer Center-South County
      • St Louis, Missouri, 미국, 63131
        • Missouri Baptist Medical Center
      • St Louis, Missouri, 미국, 63141
        • Mercy Hospital Saint Louis
      • St Louis, Missouri, 미국, 63128
        • Mercy Hospital South
      • Sullivan, Missouri, 미국, 63080
        • Missouri Baptist Sullivan Hospital
    • Montana
      • Billings, Montana, 미국, 59101
        • Billings Clinic Cancer Center
      • Bozeman, Montana, 미국, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, 미국, 59405
        • Benefis Sletten Cancer Institute
    • Nebraska
      • Bellevue, Nebraska, 미국, 68123
        • Nebraska Medicine-Bellevue
      • Kearney, Nebraska, 미국, 68847
        • CHI Health Good Samaritan
      • Omaha, Nebraska, 미국, 68114
        • Nebraska Methodist Hospital
      • Omaha, Nebraska, 미국, 68198
        • University of Nebraska Medical Center
      • Omaha, Nebraska, 미국, 68118
        • Nebraska Medicine-Village Pointe
    • Nevada
      • Las Vegas, Nevada, 미국, 89102
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, 미국, 89106
        • Radiation Oncology Centers of Nevada Central
      • Las Vegas, Nevada, 미국, 89119
        • Radiation Oncology Centers of Nevada Southeast
      • Las Vegas, Nevada, 미국, 89128
        • Comprehensive Cancer Centers of Nevada - Northwest
      • Las Vegas, Nevada, 미국, 89144
        • Comprehensive Cancer Centers of Nevada - Town Center
      • Las Vegas, Nevada, 미국, 89148
        • Comprehensive Cancer Centers of Nevada
      • Las Vegas, Nevada, 미국, 89169
        • Comprehensive Cancer Centers of Nevada - Central Valley
      • Las Vegas, Nevada, 미국, 89183
        • OptumCare Cancer Care at Fort Apache
      • Reno, Nevada, 미국, 89502
        • Renown Regional Medical Center
    • New Hampshire
      • Lebanon, New Hampshire, 미국, 03756
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
    • New Jersey
      • Basking Ridge, New Jersey, 미국, 07920
        • Memorial Sloan Kettering Basking Ridge
      • Camden, New Jersey, 미국, 08103
        • Cooper Hospital University Medical Center
      • Hackensack, New Jersey, 미국, 07601
        • Hackensack University Medical Center
      • Middletown, New Jersey, 미국, 07748
        • Memorial Sloan Kettering Monmouth
      • Montvale, New Jersey, 미국, 07645
        • Memorial Sloan Kettering Bergen
      • Voorhees Township, New Jersey, 미국, 08043
        • MD Anderson Cancer Center at Cooper-Voorhees
    • New York
      • Commack, New York, 미국, 11725
        • Memorial Sloan Kettering Commack
      • Harrison, New York, 미국, 10604
        • Memorial Sloan Kettering Westchester
      • Lake Success, New York, 미국, 11042
        • Northwell Health/Center for Advanced Medicine
      • New York, New York, 미국, 10065
        • Memorial Sloan Kettering Cancer Center
      • Rochester, New York, 미국, 14642
        • University of Rochester
      • Rochester, New York, 미국, 14620
        • Highland Hospital
      • Sleepy Hollow, New York, 미국, 10591
        • Phelps Memorial Hospital Center
      • Stony Brook, New York, 미국, 11794
        • Stony Brook University Medical Center
      • Syracuse, New York, 미국, 13210
        • State University of New York Upstate Medical University
      • The Bronx, New York, 미국, 10461
        • Montefiore Medical Center-Einstein Campus
      • The Bronx, New York, 미국, 10467
        • Montefiore Medical Center - Moses Campus
      • The Bronx, New York, 미국, 10461
        • Montefiore Medical Center-Weiler Hospital
      • Uniondale, New York, 미국, 11553
        • Memorial Sloan Kettering Nassau
      • West Islip, New York, 미국, 11795
        • Good Samaritan University Hospital
    • North Carolina
      • Hendersonville, North Carolina, 미국, 28791
        • Margaret R Pardee Memorial Hospital
      • Kenansville, North Carolina, 미국, 28349
        • ECU Health Oncology Kenansville
      • Kinston, North Carolina, 미국, 28501
        • ECU Health Oncology Kinston
      • Richlands, North Carolina, 미국, 28574
        • ECU Health Oncology Richlands
    • North Dakota
      • Bismarck, North Dakota, 미국, 58501
        • Sanford Bismarck Medical Center
      • Fargo, North Dakota, 미국, 58122
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, 미국, 58122
        • Sanford Broadway Medical Center
    • Ohio
      • Cincinnati, Ohio, 미국, 45219
        • University of Cincinnati Cancer Center-UC Medical Center
      • Cleveland, Ohio, 미국, 44109
        • MetroHealth Medical Center
      • Columbus, Ohio, 미국, 43210
        • Ohio State University Comprehensive Cancer Center
      • Dayton, Ohio, 미국, 45415
        • Dayton Physician LLC - Englewood
      • Kettering, Ohio, 미국, 45429
        • Kettering Medical Center
      • Kettering, Ohio, 미국, 45409
        • Greater Dayton Cancer Center
      • West Chester, Ohio, 미국, 45069
        • University of Cincinnati Cancer Center-West Chester
    • Oklahoma
      • Lawton, Oklahoma, 미국, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, 미국, 73104
        • University of Oklahoma Health Sciences Center
      • Oklahoma City, Oklahoma, 미국, 73120
        • Mercy Hospital Oklahoma City
    • Oregon
      • Portland, Oregon, 미국, 97239
        • Oregon Health and Science University
    • Pennsylvania
      • Allentown, Pennsylvania, 미국, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Altoona, Pennsylvania, 미국, 16601
        • UPMC Altoona
      • Beaver, Pennsylvania, 미국, 15009
        • UPMC-Heritage Valley Health System Beaver
      • Bethlehem, Pennsylvania, 미국, 18017
        • Lehigh Valley Hospital - Muhlenberg
      • Carlisle, Pennsylvania, 미국, 17015
        • Carlisle Regional Cancer Center
      • Chadds Ford, Pennsylvania, 미국, 19317
        • Christiana Care Health System-Concord Health Center
      • Danville, Pennsylvania, 미국, 17822
        • Geisinger Medical Center
      • Erie, Pennsylvania, 미국, 16505
        • UPMC Hillman Cancer Center Erie
      • Farrell, Pennsylvania, 미국, 16121
        • UPMC Cancer Center at UPMC Horizon
      • Greensburg, Pennsylvania, 미국, 15601
        • UPMC Cancer Centers - Arnold Palmer Pavilion
      • Harrisburg, Pennsylvania, 미국, 17109
        • UPMC Pinnacle Cancer Center/Community Osteopathic Campus
      • Hershey, Pennsylvania, 미국, 17033-0850
        • Penn State Milton S Hershey Medical Center
      • Johnstown, Pennsylvania, 미국, 15901
        • UPMC-Johnstown/John P. Murtha Regional Cancer Center
      • Lewisburg, Pennsylvania, 미국, 17837
        • Geisinger Medical Oncology-Lewisburg
      • McKeesport, Pennsylvania, 미국, 15132
        • UPMC Cancer Center at UPMC McKeesport
      • Mechanicsburg, Pennsylvania, 미국, 17050
        • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
      • Monroeville, Pennsylvania, 미국, 15146
        • UPMC Cancer Center - Monroeville
      • Moon Township, Pennsylvania, 미국, 15108
        • UPMC Hillman Cancer Center in Coraopolis
      • N. Huntingdon, Pennsylvania, 미국, 15642
        • Arnold Palmer Cancer Center Medical Oncology Norwin
      • New Castle, Pennsylvania, 미국, 16105
        • UPMC Hillman Cancer Center - New Castle
      • Pittsburgh, Pennsylvania, 미국, 15232
        • UPMC Hillman Cancer Center
      • Pittsburgh, Pennsylvania, 미국, 15213
        • UPMC-Magee Womens Hospital
      • Pittsburgh, Pennsylvania, 미국, 15232
        • UPMC-Shadyside Hospital
      • Pittsburgh, Pennsylvania, 미국, 15215
        • UPMC-Saint Margaret
      • Pittsburgh, Pennsylvania, 미국, 15237
        • UPMC-Passavant Hospital
      • Pittsburgh, Pennsylvania, 미국, 15243
        • UPMC-Saint Clair Hospital Cancer Center
      • Seneca, Pennsylvania, 미국, 16346
        • UPMC Cancer Center at UPMC Northwest
      • Uniontown, Pennsylvania, 미국, 15401
        • UPMC Uniontown Hospital Radiation Oncology
      • Washington, Pennsylvania, 미국, 15301
        • UPMC Washington Hospital Radiation Oncology
      • Wilkes-Barre, Pennsylvania, 미국, 18711
        • Geisinger Wyoming Valley/Henry Cancer Center
      • York, Pennsylvania, 미국, 17408
        • UPMC Memorial
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • Medical University of South Carolina
      • Greenville, South Carolina, 미국, 29605
        • Prisma Health Cancer Institute - Faris
      • Greenville, South Carolina, 미국, 29615
        • Prisma Health Cancer Institute - Eastside
      • Greer, South Carolina, 미국, 29650
        • Prisma Health Cancer Institute - Greer
      • Greer, South Carolina, 미국, 29651
        • Gibbs Cancer Center-Pelham
      • Myrtle Beach, South Carolina, 미국, 29577
        • Carolina Regional Cancer Center
      • Spartanburg, South Carolina, 미국, 29303
        • Spartanburg Medical Center
    • South Dakota
      • Sioux Falls, South Dakota, 미국, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls, South Dakota, 미국, 57104
        • Sanford Cancer Center Oncology Clinic
    • Tennessee
      • Nashville, Tennessee, 미국, 37232
        • Vanderbilt University/Ingram Cancer Center
    • Texas
      • Dallas, Texas, 미국, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Galveston, Texas, 미국, 77555-0565
        • University of Texas Medical Branch
      • Houston, Texas, 미국, 77030
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
      • Houston, Texas, 미국, 77030
        • Michael E DeBakey VA Medical Center
      • Richardson, Texas, 미국, 75080
        • UT Southwestern Clinical Center at Richardson/Plano
    • Vermont
      • Saint Johnsbury, Vermont, 미국, 05819
        • Dartmouth Cancer Center - North
    • Virginia
      • Fishersville, Virginia, 미국, 22939
        • Augusta Health Center for Cancer and Blood Disorders
    • Washington
      • Auburn, Washington, 미국, 98001
        • MultiCare Auburn Medical Center
      • Gig Harbor, Washington, 미국, 98335
        • MultiCare Gig Harbor Medical Park
      • Kirkland, Washington, 미국, 98034
        • FHCC at EvergreenHealth
      • Puyallup, Washington, 미국, 98372
        • MultiCare Good Samaritan Hospital
      • Renton, Washington, 미국, 98055
        • Valley Medical Center
      • Seattle, Washington, 미국, 98195
        • University of Washington Medical Center - Montlake
      • Seattle, Washington, 미국, 98109
        • Fred Hutchinson Cancer Center
      • Silverdale, Washington, 미국, 98383
        • Saint Joseph Medical Center Hematology and Oncology - Silverdale
      • Tacoma, Washington, 미국, 98405
        • MultiCare Tacoma General Hospital
    • West Virginia
      • Morgantown, West Virginia, 미국, 26506
        • West Virginia University Healthcare
    • Wisconsin
      • Antigo, Wisconsin, 미국, 54409
        • Aspirus Cancer Care-Antigo-Volm Cancer Center
      • Appleton, Wisconsin, 미국, 54915
        • Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
      • Ashland, Wisconsin, 미국, 54806
        • Northwest Wisconsin Cancer Center
      • Burlington, Wisconsin, 미국, 53105
        • Aurora Cancer Care-Southern Lakes VLCC
      • Eau Claire, Wisconsin, 미국, 54701
        • Marshfield Medical Center-EC Cancer Center
      • Eau Claire, Wisconsin, 미국, 54701
        • Mayo Clinic Health System-Eau Claire Clinic
      • Germantown, Wisconsin, 미국, 53022
        • Aurora Health Care Germantown Health Center
      • Grafton, Wisconsin, 미국, 53024
        • Aurora Cancer Care-Grafton
      • Green Bay, Wisconsin, 미국, 54311
        • Aurora BayCare Medical Center
      • Green Bay, Wisconsin, 미국, 54301
        • Bellin Memorial Hospital
      • Kenosha, Wisconsin, 미국, 53142
        • Aurora Cancer Care-Kenosha South
      • La Crosse, Wisconsin, 미국, 54601
        • Mayo Clinic Health System-Franciscan Healthcare
      • Marinette, Wisconsin, 미국, 54143
        • Aurora Bay Area Medical Group-Marinette
      • Marshfield, Wisconsin, 미국, 54449
        • Marshfield Medical Center-Marshfield
      • Medford, Wisconsin, 미국, 54451
        • Aspirus Medford Hospital
      • Milwaukee, Wisconsin, 미국, 53209
        • Aurora Cancer Care-Milwaukee
      • Milwaukee, Wisconsin, 미국, 53215
        • Aurora Saint Luke's Medical Center
      • Milwaukee, Wisconsin, 미국, 53233
        • Aurora Sinai Medical Center
      • Minocqua, Wisconsin, 미국, 54548
        • Marshfield Medical Center - Minocqua
      • New Richmond, Wisconsin, 미국, 54017
        • Cancer Center of Western Wisconsin
      • Oshkosh, Wisconsin, 미국, 54904
        • Vince Lombardi Cancer Clinic - Oshkosh
      • Oshkosh, Wisconsin, 미국, 54904
        • Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
      • Racine, Wisconsin, 미국, 53406
        • Aurora Cancer Care-Racine
      • Racine, Wisconsin, 미국, 53405
        • Ascension All Saints Hospital-Spring Street-Racine
      • Rice Lake, Wisconsin, 미국, 54868
        • Marshfield Medical Center-Rice Lake
      • Sheboygan, Wisconsin, 미국, 53081
        • Vince Lombardi Cancer Clinic-Sheboygan
      • Stevens Point, Wisconsin, 미국, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Stevens Point, Wisconsin, 미국, 54481
        • Aspirus Cancer Care - Stevens Point
      • Summit, Wisconsin, 미국, 53066
        • Aurora Medical Center in Summit
      • Two Rivers, Wisconsin, 미국, 54241
        • Vince Lombardi Cancer Clinic-Two Rivers
      • Wausau, Wisconsin, 미국, 54401
        • Aspirus Cancer Care-Wausau
      • Wauwatosa, Wisconsin, 미국, 53226
        • Aurora Cancer Care-Milwaukee West
      • West Allis, Wisconsin, 미국, 53227
        • Aurora West Allis Medical Center
      • Weston, Wisconsin, 미국, 54476
        • Marshfield Medical Center - Weston
      • Wisconsin Rapids, Wisconsin, 미국, 54494
        • Aspirus Cancer Care - Wisconsin Rapids

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

자격 기준

임상 연구에 참여하고자 하는 사람들이 충족해야 하는 주요 요구 사항 또는 그들이 가져야 할 특성. 자격 기준은 포함 기준(사람이 연구에 참여하는 데 필요함)과 제외 기준(사람이 참여하지 못하게 하는 것)으로 구성됩니다. 적격성 기준 유형에는 연구가 건강한 지원자를 받아들이는지, 연령 또는 연령 그룹 요구 사항이 있는지 또는 성별에 따라 제한되는지가 포함됩니다.

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • STEP 1 REGISTRATION: If this will be the first patient from a registering site to receive a given RT modality (3DCRT vs. IMRT), the site must first submit pre-RT planning documents within 3 days of Step 1 registration and receive approval from Imaging and Radiation Oncology Core (IROC) before randomizing the patient to Step 2. If this will not be the first patient to receive a specific RT modality, the patient should be immediately randomized to Step 2 on the same day.

  • STEP 2 RANDOMIZATION: If patient required review of pre-RT planning, randomization must occur within 14 days of initial registration.

  • Patients must have histologically proven, T2-T4a N0M0 urothelial carcinoma of the bladder within 120 days prior to randomization and no intervening treatment between the histologic proof and randomization. Patients with mixed urothelial carcinoma will be eligible for the trial, but the presence of small cell carcinoma will make a patient ineligible. Patients with lymph nodes >= 1.0 cm in shortest cross-sectional diameter on imaging (computed tomography [CT]/magnetic resonance imaging [MRI] of abdomen and pelvis) must have a biopsy of the enlarged lymph node showing no tumor involvement within 70 days prior to randomization. These patients may be suitable for neoadjuvant chemotherapy and radical cystectomy and are eligible for this trial if they seek out a bladder sparing treatment strategy, however patients who have received prior systemic chemotherapy for bladder cancer are not eligible for the trial.

  • Patients must undergo a transurethral resection of bladder tumor (TURBT) within 70 days prior to randomization. In a situation where a patient is referred from outside to the enrolling institution, patient must have a repeat office cystoscopy by the urologist who will be following the patient on the clinical trial to assess the adequacy of the prior TURBT. This cystoscopy can be performed in urologist office without general anesthesia. Patient may then undergo repeat TURBT if deemed necessary as standard of care by the treating urologist. Patients may have either completely or partially resected tumors as long as the treating urologist attempted maximal resection. Patient must not have T4b disease

  • Patients must undergo radiological staging within 70 days prior to randomization. Imaging of chest, abdomen, and pelvis must be performed using CT or MRI. Patients must not have evidence of T4bN1-3 disease. Eligibility is based on the local radiology report.

  • Patients with hydronephrosis are eligible if they have unilateral hydronephrosis and kidney function meets criteria specified.

  • Patients must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder within the previous 24 months except Ta/T1/carcinoma in situ (CIS) of the upper urinary tract including renal pelvis and ureter if the patient had undergone complete nephroureterectomy.

  • Patients must not have diffuse CIS based on cystoscopy and biopsy.

  • Patient must be planning to receive one of the protocol specified chemotherapy regimens.

  • All adverse events associated with any prior surgery and intravesical therapy must have resolved to Common Terminology Criteria for Adverse Events (CTCAE) grade =< 2 prior to randomization.

  • Patient must not have received any systemic chemotherapy for their bladder cancer.

  • Patient must not have had prior pelvic radiation.

  • Patients must not have received prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor.

  • Patients must not have received any systemic therapy (including, but not limited to, interferon alfa-2b, high dose IL-2, pegylated interferon [PEG-IFN], anti-PD-1, anti-PD-L1), for non-muscle invasive bladder cancer. Prior intravesical bacillus Calmette-Guerin (BCG), interferon, and intravesical chemotherapy are allowed.

  • Patients must not have received any of the following prohibited therapies within 28 days prior to randomization or be planning to receive any of the following prohibited therapies during protocol treatment:

    • Anti-cancer systemic chemotherapy or biological therapy not specified in the protocol.
    • Immunotherapy not specified in this protocol.
    • Systemic or intravesical use of any non-study anti-cancer agent (investigational or non-investigational).
    • Investigational agents other than atezolizumab.
    • Live vaccines: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed. Prior administration of intravesical BCG is allowed.
    • Glucocorticoids for any purpose other than to modulate symptoms from an event of suspected immunologic etiology. The use of physiologic doses of corticosteroids (defined as 10 mg prednisone) are acceptable, however site investigators should consult with the study chair for any dose higher than 10 mg prednisone. Dexamethasone 4 mg IV with chemotherapy to prevent nausea is allowed.
    • RANKL infusion: Concurrent denosumab (which binds the cytokine RANKL) for any known indication is prohibited due to interaction with study medication.

  • Patients must not have a major surgical procedure within 28 days prior to randomization. If patient had any surgical procedure then they should have recovered to full presurgical performance status and surgical adverse events should have resolved to grade =< 2. TURBT is not considered a major surgical procedure.

  • Patients must not have received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization. Exceptions:

    • Patients may have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea).
    • The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed. Physiological doses equivalent of 10 mg prednisone daily are allowed. Short term steroids given as antiemetic therapy, e.g. 4 mg dexamethasone or equivalent once a week, is allowed.

  • Patients must not have received a live, attenuated vaccine within 4 weeks prior to randomization or anticipate that such a live, attenuated vaccine will be required while on protocol treatment and up to 5 months after the last dose of protocol treatment.

    • Inactivated influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to randomization or while on protocol treatment and up to 5 months after the last dose of protocol treatment.

  • Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation.

  • Patients must be >= 18 years of age

  • Patient may or may not be radical cystectomy candidates.

  • Absolute neutrophil count (ANC) >= 1,500/microliter (mcL) (within 28 days prior to randomization).

  • Platelets >= 100,000/mcL (within 28 days prior to randomization).

  • Hemoglobin >= 9 g/dL (within 28 days prior to randomization).

  • Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except patients with Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL) (within 28 days prior to randomization).

  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x IULN (within 28 days prior to randomization).

  • Patients must not have clinically significant liver disease that precludes patient from treatment regimens prescribed on the study (including, but not limited to, active viral, alcoholic or other autoimmune hepatitis, cirrhosis or inherited liver disease).

  • Patients must have adequate renal function as evidenced by calculated creatinine clearance >= 25 mL/min. The creatinine used to calculate the clearance result must have been obtained within 28 days prior to randomization.

  • Patients must have Zubrod performance status =< 2.

  • Patients must have a baseline electrocardiography (ECG) performed within 30 days prior to randomization.

  • Patient must not have history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis.

  • Patients must not have an active infection requiring oral or IV antibiotics within 14 days prior to randomization. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are not eligible. If patient develops urinary tract infection after TURBT they must have recovered from the infection prior to registration.

  • Patients must not have active autoimmune disease that has required systemic treatment in past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, Graves' disease treated with methimazole or glomerulonephritis.

  • Patient must not have a history of active tuberculosis.

  • If patient has a known history of hepatitis B virus (HBV) or hepatitis C virus (HCV), they must meet the following criteria within 28 days prior to randomization.

    • Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible.
    • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).

  • Patients who are known to be positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:

    • A stable regimen of highly active anti-retroviral therapy (HAART)
    • No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
    • A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests within 28 days prior to randomization.

  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for two years. Patients with localized prostate cancer who are being followed by an active surveillance program are also eligible.

  • Female patients of childbearing potential must have a serum pregnancy test prior to randomization. Patients must not be pregnant or nursing due to the potential teratogenic side effects of the protocol treatment. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of protocol treatment, and for 5 months (150 days) after the last dose of all study drugs. A woman is considered to be of "reproductive potential" if she has had a menses at any time in the preceding 12 consecutive months.

  • Patients must not be known to be allergic to Chinese hamster egg or ovary cell products and must not have any known major allergic reactions to any study drug.

  • Patients must be offered the opportunity to participate in specimen banking for future studies.

  • Patients who can complete Patient-Reported Outcome instruments in English or Spanish must agree to complete the EORTC QLQ-C30, the EORTC QLQ-BLM30, the EPIC Bowel Assessment, and the EQ-5D-5L per protocol schedule of assessment.

  • As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔

참가자 그룹 / 팔

시험 프로토콜에 따라 특정 중재/치료를 받거나 중재를 받지 않는 임상 시험 참가자 그룹 또는 하위 그룹입니다.
개입 / 치료

개입 / 치료

임상 연구의 초점이 되는 프로세스 또는 작업입니다. 개입에는 약물, 의료 기기, 절차, 백신 및 조사 중이거나 이미 사용 가능한 기타 제품이 포함됩니다. 개입에는 교육이나 식이요법 및 운동 수정과 같은 비침습적 접근법도 포함될 수 있습니다.
활성 비교기: Arm I (RT, chemotherapy)

Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine IV twice weekly for 6 weeks concurrent with RT, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.
다른: Quality-of-Life Assessment

Ancillary studies

다른 이름들:
  • 삶의 질 평가
의약품: Cisplatin

Given IV

다른 이름들:
  • CDDP
  • 시스-디암민디클로리도백금
  • 시스마플라트
  • 시스플라티넘
  • 네오플라틴
  • 플라티놀
  • 아비플라틴
  • 블라스톨렘
  • 브리플라틴
  • 시스-디아민-디클로로백금
  • 시스-디아민디클로로 백금(II)
  • 시스-디아민디클로로백금
  • 시스-디클로로암민 백금(II)
  • 시스-백금 디아민 디클로라이드
  • 시스-백금
  • 시스-백금 II
  • 시스-백금 II 디아민 디클로라이드
  • 시스플라티나
  • 시스플라틸
  • 치토플라티노
  • 시토신
  • DDP
  • 레더플라틴
  • 메타플라틴
  • Peyrone의 염화물
  • 페이론의 소금
  • 플라시스
  • 플라스티스틸
  • 플라타민
  • 플라티블라스틴
  • 플라티블라스틴-S
  • 플래티넥스
  • 플라티놀-AQ
  • 플라티놀-AQ VHA 플러스
  • 플라티녹산
  • 백금
  • 백금 디암미노디클로라이드
  • 플라티란
  • 플라티스틴
  • 플라토신
의약품: Fluorouracil

Given IV

다른 이름들:
  • 5-플루라실
  • 플루라실
  • 5 플루오로우라실
  • 5 플루오로우라실룸
  • 5푸
  • 5-플루오로-2,4(1H,3H)-피리미딘디온
  • 5-플루오로우라실
  • 5-푸
  • 5FU
  • AccuSite
  • 카라크
  • 플루오로 우라실
  • 플루우라실
  • 플루라블라스틴
  • 플루라세딜
  • 플루릴
  • 플루로블라스틴
  • 리보플루오르
  • 로 2-9757호
  • Ro-2-9757
의약품: Gemcitabine

Given IV

다른 이름들:
  • dFdCyd
  • dFdC
  • 디플루오로데옥시시티딘
절차: Cystoscopy

Undergo a cystoscopy

다른 이름들:
  • 씨에스
의약품: Mitomycin

Given IV

다른 이름들:
  • 무타마이신
  • 아메티신
  • 젤미토
  • 미토
  • 미토씨
  • 미토메닥
  • 미토신
  • 미토신-C
  • 미톨렘
  • 미토마이신 C
  • 미토마이신-C
  • 미토마이신-X
  • 미토솔
  • 미토지트렉스
  • NCI-C04706
  • 미토마이신 pyelocalyceal
다른: Survey Administration

Ancillary studies

절차: Biopsy of Bladder

Undergo a bladder biopsy

다른 이름들:
  • 방광 생검
절차: Computed Tomography

Undergo CT or MRI

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형
절차: Magnetic Resonance Imaging

Undergo CT or MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
방사능: Radiation Therapy

Undergo 3DCRT or IMRT

다른 이름들:
  • 암 방사선 요법
  • ENERGY_TYPE
  • 비추다
  • 조사
  • 방사능
  • 방사선 요법, NOS
  • 방사선 요법
  • RT
  • 치료, 방사선
  • 에너지 종류
절차: Transurethral Resection of Bladder Tumor

Undergo a TURBT

다른 이름들:
  • 경요도 절제술(TURBT)
  • TURBT
실험적: Arm II (RT, chemotherapy, atezolizumab)

Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.
다른: Quality-of-Life Assessment

Ancillary studies

다른 이름들:
  • 삶의 질 평가
의약품: Cisplatin

Given IV

다른 이름들:
  • CDDP
  • 시스-디암민디클로리도백금
  • 시스마플라트
  • 시스플라티넘
  • 네오플라틴
  • 플라티놀
  • 아비플라틴
  • 블라스톨렘
  • 브리플라틴
  • 시스-디아민-디클로로백금
  • 시스-디아민디클로로 백금(II)
  • 시스-디아민디클로로백금
  • 시스-디클로로암민 백금(II)
  • 시스-백금 디아민 디클로라이드
  • 시스-백금
  • 시스-백금 II
  • 시스-백금 II 디아민 디클로라이드
  • 시스플라티나
  • 시스플라틸
  • 치토플라티노
  • 시토신
  • DDP
  • 레더플라틴
  • 메타플라틴
  • Peyrone의 염화물
  • 페이론의 소금
  • 플라시스
  • 플라스티스틸
  • 플라타민
  • 플라티블라스틴
  • 플라티블라스틴-S
  • 플래티넥스
  • 플라티놀-AQ
  • 플라티놀-AQ VHA 플러스
  • 플라티녹산
  • 백금
  • 백금 디암미노디클로라이드
  • 플라티란
  • 플라티스틴
  • 플라토신
의약품: Fluorouracil

Given IV

다른 이름들:
  • 5-플루라실
  • 플루라실
  • 5 플루오로우라실
  • 5 플루오로우라실룸
  • 5푸
  • 5-플루오로-2,4(1H,3H)-피리미딘디온
  • 5-플루오로우라실
  • 5-푸
  • 5FU
  • AccuSite
  • 카라크
  • 플루오로 우라실
  • 플루우라실
  • 플루라블라스틴
  • 플루라세딜
  • 플루릴
  • 플루로블라스틴
  • 리보플루오르
  • 로 2-9757호
  • Ro-2-9757
의약품: Gemcitabine

Given IV

다른 이름들:
  • dFdCyd
  • dFdC
  • 디플루오로데옥시시티딘
의약품: Atezolizumab

Given IV

다른 이름들:
  • 티센트릭
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA
  • RG-7446
  • RG 7446
  • RO 5541267
  • RO-5541267
절차: Cystoscopy

Undergo a cystoscopy

다른 이름들:
  • 씨에스
의약품: Mitomycin

Given IV

다른 이름들:
  • 무타마이신
  • 아메티신
  • 젤미토
  • 미토
  • 미토씨
  • 미토메닥
  • 미토신
  • 미토신-C
  • 미톨렘
  • 미토마이신 C
  • 미토마이신-C
  • 미토마이신-X
  • 미토솔
  • 미토지트렉스
  • NCI-C04706
  • 미토마이신 pyelocalyceal
다른: Survey Administration

Ancillary studies

절차: Biopsy of Bladder

Undergo a bladder biopsy

다른 이름들:
  • 방광 생검
절차: Computed Tomography

Undergo CT or MRI

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형
절차: Magnetic Resonance Imaging

Undergo CT or MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
방사능: Radiation Therapy

Undergo 3DCRT or IMRT

다른 이름들:
  • 암 방사선 요법
  • ENERGY_TYPE
  • 비추다
  • 조사
  • 방사능
  • 방사선 요법, NOS
  • 방사선 요법
  • RT
  • 치료, 방사선
  • 에너지 종류
절차: Transurethral Resection of Bladder Tumor

Undergo a TURBT

다른 이름들:
  • 경요도 절제술(TURBT)
  • TURBT

연구는 무엇을 측정합니까?

주요 결과 측정

주요 결과 측정

임상 연구 프로토콜에서 개입/치료의 효과를 평가하는 데 가장 중요한 계획된 결과 측정. 대부분의 임상 연구에는 하나의 주요 결과 측정이 있지만 일부는 둘 이상입니다.
결과 측정
측정값 설명
기간
Bladder intact event-free survival (BI-EFS)
기간: From the date of randomization to the first documentation of a BI-EFS event, assessed up to 5 years

At each time point, futility will be evaluated, and in the latter two analyses, efficacy will also be evaluated as specified. The final BI-EFS intent-to-treat analysis will be conducted using a stratified logrank test stratifying on stratification factors, and testing treatment at the one-sided significance level of 0.022 to account for multiple interim testing. The hazard ratio (HR) will be estimated using a stratified Cox proportional hazards model and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median BI-EFS for each treatment arm.
From the date of randomization to the first documentation of a BI-EFS event, assessed up to 5 years

2차 결과 측정

2차 결과 측정

임상 연구 프로토콜에서 개입의 효과를 평가하기 위한 1차 결과 측정만큼 중요하지는 않지만 여전히 관심이 있는 계획된 결과 측정입니다. 대부분의 임상 연구에는 하나 이상의 2차 결과 측정이 있습니다.
결과 측정
측정값 설명
기간
암 특이 생존
기간: 무작위배정일부터 방광암으로 인한 사망일까지, 최대 5년 평가
무작위배정일부터 방광암으로 인한 사망일까지, 최대 5년 평가
Overall survival (OS)
기간: From date of randomization to death from any cause, assessed up to 5 years

Will be estimated using Kaplan-Meier methodology for each treatment arm. Will be analyzed using a similar method as for BI-EFS.
From date of randomization to death from any cause, assessed up to 5 years
Modified bladder intact event-free survival (mBI-EFS)
기간: From date of randomization to the first documentation of a mBI-EFS event, assessed within 90 days

Analysis of modified BI-EFS, i.e., a sensitivity analysis of BI-EFS, where bladder cancer event is defined as histologically proven presence of muscle invasive bladder cancer, clinical evidence of nodal or metastatic disease, radical cystectomy, or death within 90 days of receiving protocol specified treatment, will also be conducted.
From date of randomization to the first documentation of a mBI-EFS event, assessed within 90 days
Biopsy response
기간: At 18 weeks

The Cochran-Mantel-Haenszel statistic will be used with modified ridit scores to evaluate the biopsy outcomes of complete response versus (vs.) down-staging vs. no response for the two treatment arms.
At 18 weeks
Complete response duration
기간: From the date of the biopsy documenting the complete response to the time of muscle invasive recurrence, local progression, evidence of metastatic disease or death due to any cause, assessed at 18 weeks

For the subset of patients who achieve a complete response during the week 18 biopsy window, complete response duration is defined from the date of the biopsy documenting the complete response to the time of muscle invasive recurrence, local progression, evidence of metastatic disease or death due to any cause. Will be analyzed using a similar method as for BI-EFS.
From the date of the biopsy documenting the complete response to the time of muscle invasive recurrence, local progression, evidence of metastatic disease or death due to any cause, assessed at 18 weeks
Progression-free survival
기간: From date of randomization to first radiologic or histologic evidence of local progression, nodal or distant metastasis, or death due to any cause, assessed up to 5 years

Will be estimated using Kaplan-Meier methodology for each treatment arm. Will be analyzed using a similar method as for BI-EFS.
From date of randomization to first radiologic or histologic evidence of local progression, nodal or distant metastasis, or death due to any cause, assessed up to 5 years
Metastasis-free survival
기간: From date of randomization to first radiologic or histologic evidence of metastatic disease or death due to any cause, assessed up to 5 years

Will be estimated using Kaplan-Meier methodology for each treatment arm. Will be analyzed using a similar method as for BI-EFS.
From date of randomization to first radiologic or histologic evidence of metastatic disease or death due to any cause, assessed up to 5 years
Quality of life
기간: Baseline up to 5 years

Assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ)-C30. Will be examined using linear mixed models with patient considered as the random effect. The baseline physical function score and the stratification factors will be included in the regression model as adjustment covariates.
Baseline up to 5 years

기타 결과 측정

기타 결과 측정

임상 시험의 경우 참가자에 대한 개입/치료의 효과를 결정하는 데 사용되는 프로토콜에 설명된 계획된 측정입니다. 관찰 연구에서 질병이나 특성의 패턴 또는 노출, 위험 요인 또는 치료와의 연관성을 설명하는 데 사용되는 측정 또는 관찰입니다. 결과 측정 유형에는 1차 결과 측정과 2차 결과 측정이 포함됩니다.
결과 측정
측정값 설명
기간
Treatment interactions
기간: Up to 5 years

A Cox regression model will be used to evaluate the main effects of treatment arm and the main effect for each stratification factor and the interaction of the stratification factor with treatment in terms of both the primary endpoint and secondary endpoints. The stratification factors to be evaluated include: (1) clinical stage T2 vs. T3/T4a, (2) intended chemotherapy regimen cisplatin vs. 5-FU + mitomycin-C vs. gemcitabine, (3) radiation field small pelvis vs. bladder only and (4) performance status 0-1 vs. 2. There may be other radiation summary measures that may also be explored in terms of their modification of the experimental treatment effect including extent of radiation to lymph node fields. Subgroup analysis defined by stratification factors will also be conducted for primary endpoint and key secondary.
Up to 5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

스폰서

연구를 시작하고 연구에 대한 권한과 통제권을 가진 조직 또는 사람.
National Cancer Institute (NCI)

수사관

수사관

임상 연구에 참여하는 연구원. 관련 용어에는 사이트 주임 조사관, 사이트 하위 조사자, 연구 의자, 연구 책임자 및 연구 주임 조사관이 포함됩니다.
  • 수석 연구원: Parminder Singh, SWOG Cancer Research Network

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

연구 시작

첫 번째 참가자가 임상 연구에 등록된 실제 날짜입니다. "예상" 연구 시작 날짜는 연구자가 연구 시작 날짜가 될 것이라고 생각하는 날짜입니다.
2019년 6월 3일

기본 완료 (추정된)

기본 완료

임상 연구의 마지막 참가자가 1차 결과 측정을 위한 최종 데이터를 수집하기 위해 검사를 받거나 개입을 받은 날짜입니다. 임상 연구가 프로토콜에 따라 종료되었는지 또는 종료되었는지 여부는 이 날짜에 영향을 미치지 않습니다. 완료 날짜가 다른 1차 결과 측정이 둘 이상인 임상 연구의 경우 이 용어는 모든 1차 결과 측정에 대한 데이터 수집이 완료된 날짜를 나타냅니다. "예상" 기본 완료 날짜는 연구원이 연구의 기본 완료 날짜가 될 것이라고 생각하는 날짜입니다.
2027년 6월 1일

연구 완료 (추정된)

연구 완료

임상 연구의 마지막 참가자가 1차 결과 측정, 2차 결과 측정 및 부작용(즉, 마지막 참가자의 마지막 방문)에 대한 최종 데이터를 수집하기 위해 검사를 받거나 중재/치료를 받은 날짜입니다. "예상" 연구 완료 날짜는 연구원이 연구 완료 날짜가 될 것이라고 생각하는 날짜입니다.
2027년 6월 1일

연구 등록 날짜

최초 제출

최초 제출

연구 후원자 또는 연구자가 최초로 ClinicalTrials.gov에 연구 기록을 제출한 날짜. 일반적으로 처음 제출한 날짜와 ClinicalTrials.gov에서 기록을 사용할 수 있는 날짜(첫 게시 날짜) 사이에는 며칠의 지연이 있습니다.
2018년 12월 12일

QC 기준을 충족하는 최초 제출

QC 기준을 충족하는 최초 제출

연구 스폰서 또는 연구자가 국립 의학 도서관(NLM) 품질 관리(QC) 검토 기준과 일치하는 연구 기록을 처음 제출한 날짜입니다. 의뢰자 또는 조사자는 NLM의 QC 검토 기준이 충족되기 전에 연구 기록을 한 번 이상 수정하고 제출해야 할 수 있습니다. 연구 기록이 NLM QC 검토 기준과 일치하는지 확인하는 것은 후원자 또는 조사자의 책임입니다.
2018년 12월 12일

처음 게시됨 (실제)

처음 게시됨

National Library of Medicine(NLM) 품질 관리(QC) 검토가 완료된 후 ClinicalTrials.gov에서 연구 기록을 처음 사용할 수 있는 날짜입니다. 일반적으로 연구 후원자 또는 연구자가 연구 기록을 제출한 날짜와 처음 게시된 날짜 사이에는 며칠의 지연이 있습니다.
2018년 12월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

마지막 업데이트 게시됨

ClinicalTrials.gov에서 연구 기록이 변경된 가장 최근 날짜. 연구 후원자 또는 연구자가 변경 사항을 ClinicalTrials.gov에 제출한 시점(마지막 업데이트 제출 날짜)과 마지막 업데이트 게시 날짜 사이에 지연이 있을 수 있습니다.
2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

QC 기준을 충족하는 마지막 업데이트 제출

연구 후원자 또는 연구자가 국립 의학 도서관(NLM) 품질 관리(QC) 검토 기준과 일치하는 연구 기록에 대한 변경 사항을 제출한 가장 최근 날짜. 연구 기록이 NLM QC 검토 기준과 일치하는지 확인하는 것은 후원자 또는 조사자의 책임입니다.
2026년 11월 10일

마지막으로 확인됨

마지막으로 확인됨

연구 후원자 또는 조사자가 ClinicalTrials.gov에서 임상 연구에 대한 정보가 정확하고 최신 정보라고 확인한 가장 최근 날짜. 모집 상태가 모집인 연구인 경우; 아직 모집하지 않았습니다. 또는 활성, 비모집이 지난 2년 이내에 확인되지 않은 경우 연구의 모집 상태는 알 수 없음으로 표시됩니다.
2026년 8월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

기타 연구 ID 번호

연구 후원자, 기금 제공자 또는 다른 사람이 임상 연구에 할당한 NCT 번호 이외의 식별자 또는 ID 번호. 이 번호에는 다른 시험 등록의 고유 식별자와 미국 국립보건원(National Institutes of Health) 보조금 번호가 포함될 수 있습니다.
  • NCI-2018-03264
  • U10CA180888 (미국 NIH 보조금/계약)
  • NCI-2018-03264 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • S1806 (기타 식별자: CTEP)
  • S1806 (기타 식별자: SWOG)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

쿠키 설정

당사는 당사 웹 사이트에서 최상의 경험을 제공하기 위해 쿠키를 사용합니다. 자세한 내용은 개인 정보 보호 및 쿠키 정책 을주의 깊게 읽어보십시오. ...>>>귀하는 정책에 설명 된대로 귀하의 웹 사이트 또는 컴퓨터에서 쿠키를 삭제하여 언제든지 귀하의 기본 설정을 변경하거나 동의를 철회 할 수 있습니다. 동의하고 아래 "설정 관리"섹션에서 해당 상자를 선택하여 기본 설정을 선택하십시오. 이 웹 사이트의 일부를 사용하기 전에 서비스 약관 을주의 깊게 읽어 보시기 바랍니다.
«설정 관리